Alpha 1 Antitrypsin Deficiency Treatment Market Research Report Forecast to 2025

A recent intelligence study by Transparency Market Research (TMR) has detected that the global alpha-1 antitrypsin deficiency treatment market is divided among a vast number of global and regional players. The report anticipates that this fragmented scenario of the market for alpha-1 antitrypsin will prompt an increase in the number of mergers and acquisitions that can benefit both parties. Some of the key companies in the global alpha-1 antitrypsin deficiency treatment market identified by the report are: Baxter, Pfizer Inc., Boehringer Ingelheim GmbH, AstraZeneca, Grifols S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Shire plc, CSL Behring LLC, LFB Biomedicaments S.A., and Kamada Ltd.

Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/alpha-1-antitrypsin-deficiency-treatment-market.html

As per the projections of the TMR report, the demand in the global alpha-1 antitrypsin deficiency treatment market will augment at formidable CAGR of 10.3% during the forecast period of 2017 to 2025, estimated to reach a valuation of US$2,908.1 mn by the end of 2025, remarkably up from its evaluated worth of US$1,224.5 mn in 2016. In the near future, a number of new biotechnology companies are expected to have a foray in the alpha-1 antitrypsin deficiency treatment market, developing novel treatment processes, personalized medicines for genetically inherited disorders, and invest on the research and development of stem cell based therapeutics.

Based on treatment type, in 2016, the augmentation therapy segment served the maximum demand, whereas bronchodilator treatment earned a strong second position in terms of volume of demand. Parenteral route of administration is leading over oral and inhalation methods, while hospital is the most important end-user category. Geographically, North America the most profitable region for the stockholders of the global alpha-1 antitrypsin deficiency treatment market, with prevalence of alpha-1 antitrypsin deficiency, increasing diagnosis rate, high plasma yield, and high per capita health care expenditure.

Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13214

Prevalence of respiratory disease worldwide, recent advancements in the diagnosis of apha-1 antitrypsin deficiency, increased government support in several emerging economies for the improvement of healthcare facilities, high unmet demands in both developed and developing regions, and novel product opportunities are some of the key factors driving the demand in the global apha-1 antitrypsin deficiency treatment market.

As per estimation of the Forum of International Respiratory Societies (FIRS), more than 200 million people are affected by COPD, which is emerging as the fourth leading cause of death across the world by 2030. On the other hand, asthma is detected in about 235 million people globally. With technological improvements, production and purification processes of alpha-1 antitrypsin are now much safer and free from virus, protein, and other contaminants. This has increased clinician preference for usage of plasma products. This in turn is expected to boost demand for plasma-derived products such as alpha-1 antitrypsin and IVIG.

According to the Alpha-1 Foundation, up to 3% of all people who are diagnosed with chronic obstructive pulmonary disease (COPD) may have undetected alpha-1 antitrypsin deficiency. As a result, AlphaKit QuickScreen has been developed by Grifols, a diagnostic kit that aids in quick identification of the mutated Z gene. On the other hand, stringent regulations, limited plasma fractionation capacity, shortage of alpha-1 antitrypsin supply, and high cost of drugs are a few factors challenging the global anti-trypsin deficiency treatment market from attaining its true potential. The vendors of this market are expected to gain new opportunities via strategic alliances, patient assistance programs, and increasing awareness about therapy.

Purchase this Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=13214<ype=S

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.